35 71

Cited 0 times in

Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis

DC FieldValueLanguage
dc.contributor.author김종원-
dc.contributor.author이주용-
dc.contributor.author조강수-
dc.contributor.author홍창희-
dc.date.accessioned2020-02-11T06:11:29Z-
dc.date.available2020-02-11T06:11:29Z-
dc.date.issued2019-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/174577-
dc.description.abstractTreatment-related adverse events (AEs) can obfuscate the maintenance of a conventional schedule of sunitinib in patients with metastatic renal cell carcinoma. Accordingly, alternative schedules seeking to improve the safety profile of sunitinib have been tested. Recently, two meta-analyses similarly described improved safety profiles favoring a two weeks on and one week off (2/1) schedule, but with conflicting results for survival outcomes. Therefore, we conducted an updated systematic review and meta-analysis, including all recently published studies and using complementary statistical methods. Endpoints included progression-free survival, overall survival, and AEs of 15 types. Eleven articles were included in this meta-analysis. Using adjusted findings, we noted statistically better results in progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.39-0.84; p = 0.005), but no difference in overall survival (hazard ratio, 0.66; 95% confidence interval, 0.42-1.04; p = 0.08). Moreover, the 2/1 schedule was beneficial for reducing the incidence of several AEs. Conclusively, our meta-analysis suggests that the 2/1 schedule holds promise as an alternative means of reducing AEs and maintaining patient quality of life. While the survival outcomes of the 2/1 schedule seem also to be favorable, the level of evidence for this was low, and the interpretation of these findings should warrant caution. Large scale randomized trials are needed to support these results.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfCANCERS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleDoes an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨의학교실)-
dc.contributor.googleauthorDoo Yong Chung-
dc.contributor.googleauthorDong Hyuk Kang-
dc.contributor.googleauthorJong Won Kim-
dc.contributor.googleauthorDo Kyung Kim-
dc.contributor.googleauthorJoo Yong Lee-
dc.contributor.googleauthorChang Hee Hong-
dc.contributor.googleauthorKang Su Cho-
dc.identifier.doi10.3390/cancers11121830-
dc.contributor.localIdA04731-
dc.contributor.localIdA03161-
dc.contributor.localIdA03161-
dc.contributor.localIdA03801-
dc.contributor.localIdA03801-
dc.contributor.localIdA04447-
dc.contributor.localIdA04447-
dc.relation.journalcodeJ03449-
dc.identifier.eissn2072-6694-
dc.identifier.pmid31766332-
dc.subject.keywordadverse events-
dc.subject.keywordalternative dosing-
dc.subject.keywordmeta-analysis-
dc.subject.keywordrenal cell carcinoma-
dc.subject.keywordsunitinib-
dc.subject.keywordsurvival outcomes-
dc.subject.keywordsystematic review-
dc.contributor.alternativeNameKim, Jong Won-
dc.contributor.affiliatedAuthor김종원-
dc.contributor.affiliatedAuthor이주용-
dc.contributor.affiliatedAuthor이주용-
dc.contributor.affiliatedAuthor조강수-
dc.contributor.affiliatedAuthor조강수-
dc.contributor.affiliatedAuthor홍창희-
dc.contributor.affiliatedAuthor홍창희-
dc.citation.volume11-
dc.citation.number12-
dc.citation.startPageE1830-
dc.identifier.bibliographicCitationCANCERS, Vol.11(12) : E1830, 2019-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.